

References

- * **Ahmed A., Saleh A., El Etriby A., and Dardir D.:** Incidence of Hyperhomocysteinemia in Ischemic Egyptian Males. Thesis for Partial Fulfillment of Master Degree of Cardiology; Ain Shams University (2000).
- * **Akira T., Toru W., Yoshiaki M. and Musaru N.** Serum Lipoprotein (a) Concentrations are Related to Coronary Disease Progression Without New Myocardial Infarction. *Br Heart J*; 74: 365-369. (1995).
- * **Alan F. and H. Robert S.** Lipoproteins and Atherosclerosis- The Role of HDL Cholesterol, Lp (a), and LDL Particle Size. American College of Cardiology 48 th Annual Scientific Session March 7-10, 1999 ACC'99.
- * **Amy K.** From the Issue of Physician Assistant Coronary Artery Disease Risk Factors: The Future of Prevention. 204-207 (April 2000).
- * **Andreas N., Thomas W., Hans D., Christian J., Nicolette M., Jan H., and Ulrike B.** Identification of Megalin / gp 330 as a Receptor for Lipoprotein (a) In Vitro. *Arterioscler. Thromb. Vasc. Biol.*; 19: 552-561. (1999).
- * **Andrew G., Adrienne C., Jennifer L., Jose M., Leo J., Peter W., Ernst J. and William P.:** Elevated Plasma Lipoprotein (a) and Coronary Heart Disease in Men Aged 55 Years and Younger. A Prospective Study. *JAMA*; 276: 544-548. (1996).
- * **Angelo M. and Gunther M.:** Lipoprotein (a) Heterogeneity and Biological Relevance. *J. Clin. Invest.*; 85: 1709-1715. (June 1990).
- * **Angelo M., Richard M., and Kare B.** Lipoprotein(a) and Atherosclerosis. *Annals of Internal Medicine*; 115: 209-218. (1991).

- * *Angles-Cano, E., Marcovina, S., Koschinsky M.* High Antifibrinolytic Activity of Lipoprotein(a) Containing Small Apolipoprotein(a) Isoforms Response. *Circulation* 102:el84-185 (2000).
- * *Annika R., Lars W., Elsa E., Bo R., and Hans W.* Lipoprotein (a) and Coronary Heart Disease: a Prospective Case Control Study in a General Population Sample of Middle Aged Men. *BMJ*; 301: 1248-51 (1990).
- * *Armstrong W., Cremer P., Eberle E. et al.* The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. *Arteriosclerosis* 62 : 249-257. (1986)
- * *Arzu G., Jeffrey M., Gerhard K., Nicholas M.* Papadopoulos and H. Bryan Brewer Jr. Levels of Lipoprotein Lp (a) Decline with Neomycin and Niacin Treatment. *Atherosclerosis*; 57: 293-301. (1985).
- * *Becerra A, Bellido D, Luengo A, Piedrola G and De Luis DA.* Lipoprotein (a) and Other Lipoproteins in Hypothyroid Patients Before and After Thyroid Replacement Therapy. *Clin Nutr*; 18 (5):319-22. 1999 Oct.
- * *Bernard C., France G., Sital M., Jean P., and Gilles R.* Dagenais. Is Lipoprotein(a) an Independent Risk Factor for Ischemic Heart Disease in Men? The Quebec Cardiovascular Study. *JACC*; 31: 519-25 (1998).
- * *Bersot, T., Pitas S., Rall L., and Mahley, R.* Fat Feeding in Human Induces Lipoproteins of Density Less Than 1.006 That are Enriched in Apolipoprotein(a) and that Cause Lipid Accumulation in Macrophages. *J. Clin. Invest.* 77: 622-630. (1986).

- * : **Braunwald E., Bernard J. Gersh and John D. Rutherford.** Chronic coronary artery disease in Heart Disease Textbook of cardiovascular Medicine. Braunwold E. (6th ed), W.B. Saunders Co., Philadelphia, 38:1290. (2001).

- * **Brazier L., Tired L., Lue G., Arveiler D., Ruidavets JB., Evans A., Chapman J., Cambin F., and Thillet J.:** Sequence Polymorphisms in the Apolipoprotein (a) Gene and Their Association With Lipoprotein (a) Levels and Myocardial Infarction. The ECTM Study. Atherosclerosis; 144 (2): 323-33. 1999 Jun.

- * : **Brown G., Albers J., and Eisher U.** Regression of CAD as a Result of Intensive Lipid Lowering Therapy in Men With High Level of Apolipoprotein B. N Engl J Med; 323:1289. (1990).

- * **Burrin J., and Price C.:** Measurment of Blood Glucose. Clin. Chem., 22:37 (1985).

- * **Castelli W., Garrison R., Wilson P., Abbott R., Kalousdian S., and Kannel W.:** Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels. J Am Med Assoc; 256:2835, (1986).

- * : **Charles S., Michel M., Eva W., and Lucien C.:** Relation of Coronary Artery Disease in Women < 60 Years of Age to the Combined Elevation of Serum Lipoprotein (a) and Total Cholesterol to High-Density Cholesterol Ratio. The American Journal of Cardiology; December 1; 72:17 (1993).

- * **Chiarugi L, Prisco D, Antonucci E, Capanni M, Fedi S, Liotta AA, Margheri M, Simonetti I, and Gensini GF.** Lipoprotein (a) and Anticardiolipin Antibodies are Risk Factors for Clinically Relevant Restenosis After Elective Balloon Percutaneous Transluminal Coronary Angioplasty. Atherosclerosis; 154(1):129-35 (Jan; 2001).

- * **Cobbaert C., Jukema Jw, zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV.** Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol Regression Growth Evaluation Statin Study(REGRESS). J Am Coll Cardiol 30 (6) : 1491-9. (1997).

- * **Cooke R., Sheahan D., Foley M., Reilly W., and Walsh M.:** Lipoprotein (a) in Restenosis After Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Disease. Circulation. 89: 1593-1598. (1994).

- * **Cooper G., Smith S., and Wiebe D.** International Survey of Apolipoprotein AI and B Measurements (1983-1984). Clinical Chemistry, 30: 223-228, (1985).

- * **Criqui M., Mebane I., Wallace R., Heiss G., and Holdbrook M.:** Multivariate Correlates of Adult Blood Pressures in Nine North American Populations. Prev Med; 11:391. (1982).

- * **Dan L., Gunther M., William J., John W., and Angelo M.** Partial Amino Acid Sequence of Apolipoprotein (a) Shows That It Is Homologous to Plasminogen. Proc. Natl. Acad. Sci. USA. Vol. 84: 3224-3228, May, (1987).

- * **Danesh J., Collins R. and Peto R.,** Lipoprotein(a) and Coronary Heart Disease: Meta Analysis of Prospective Studies. Circulation 102: 1082-1085 (2000).

- * **Dangas G., Mehran R., Harpel PC, Sharma SK, Dube G., Marcovina SM., Ambrose JA. and Fallon JT.** Lipoprotein(a) and inflammation in human coronary atherosclerosis association with the severity of clinical presentation. J Am, Coll Cardio 32,2035-2042

(1998).

- * **David C., and John A.:** Coronary Arteriography In Heart Disease A Textbook of Cardiovascular Medicine. Braunwold E. (5th ed), W.B. Saunders Co., Philadelphia, 8:240. (1997).
- * **David H., Sharon A., Ruth L., Stanley P., and Linda C.** Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts. JAMA June 19, Vol 257, No. 23. (1987).
- * **David J., Paul M. and Thomas A.** Pearson Risk Factors and the Prevention of Coronary Heart Disease. HURST'S THE HEART Text Book Ninth Edition, Library of congress 1175-1195. (1998).
- * **David J., Richard A., Robert S., John E., Caral C., Robert D., Eric B., Helen H. and David H.:** Relation of Plasma Lipoprotein (a) to Infarct Artery Patency in Survivors of Myocardial Infarction. Circulation; 88: 935-940. (1993).
- * **DeNofrio D., Desai S., Rader DJ., Chang G., Kelley MP, Acker MA. and Loh E:** Changes in Lipoprotein (a) Concentration After Orthotopic Heart Transplantation. Am. Heart J.; 139 (4): 729-33. (Apr. 2000).
- * **Ezhov MV, Afanas'eva OI, Benevolenskaia GF, Savchenko AP, Balakhonova TV, Liakishev AA and Pokrovskii SN.** Association of Lipoprotein (a) and Apolipoprotein (a) Phenotypes With Coronary and Carotid Atherosclerosis in CHD Men. Ter Arkh; 72 (1): 28-32. (2000).
- * **Flavio R., Giuseppe S., Antonio D., Antonello V., Valeria F., Terenzio C., Silvia G., and Eugenio U.:** Plasma Lipoprotein(a) Is Not a Predictor for Restenosis After Elective High-Pressure Coronary Stenting. Circulation; 98:1172-1177 (1998).

- * **Fortmann, S., and Marcovina. S.** Lipoprotein (a), Elusive Lipoprotein(a) particle . Circulation 95: 295-296. (1997).

- * **Franklin L.,** Outline The Cholesterol - Atherosclerosis Connection Lipid Metabolism Atherogenesis Risk Factors (modifiable and non-modifiable) Classification of Dyslipidemias Primary, Secondary Dyslipidemias, and Clinical Trials. <http://www.cvmg.com/cholest.html> (1997).

- * **Fraser B., Robert B., Eugene L., May R., James B., Susan D., Eileen S., Renee R., Jane L., Sabera V., Bernard M., Parvez S. and John H.:** Relation Between Circadian Patterns in Levels of Circulating Lipoprotein (a), Fibrinogen, Platelets, and Related Lipid Variables in Men. Am Heart J 139 (1): 164-173, (2000).

- * **Freedman, D., Srinivasan S., and Shear C.** The Relation of Apolipoproteins AI and B in Children to Parental Myocardial Infarction. N. Engl. J. Med., 315: 721-726, (1986).

- * **Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanbe Y, Mutou M, Ishikawa S, Ogyuu A, Ashikawa K and Maruyama Y.:** Lipoprotein (a) is a Potential Coronary Risk Factor. Jpn Circ J; 64(1): 51-6. (Jan. 2000). (PubMed medline).

- * **Gaubatz W., Karima I., Juan G. and Morrisett D.** Polymorphic Forms of Human Apolipoprotein(a): Inheritance and Relationship of Their Molecular Weights to Plasma Levels of Lipoprotein(a). J. Lipid Res. 31: 603-613. (1990).

- * **Gavish D. and Breslow J.** Lipoprotein (a) reduction by N-acetylcysteine. Lancet 337 : 203 – 204. (1991).

- * **Gavish D., Neal A., and Jan L.** Plasma Lp (a) Concentration Is Inversely Correlated With the Ratio of kringle IV/Kringle V Encoding Domains in the Apo (a) Gene. *J. Clin. Invest.* 84: 2021-2027. December; (1989).
- * **Genest J., McNamara JR., and Ordovas JM.** Lipoprotein Cholesterol, Apolipoprotein A-1 and B and Lipoprotein (a) Abnormalities in Men With Pre-Mature Coronary Heart Disease. *J Am Coll Cardiol.* 19: 792-802; (1992).
- * **Genest J., McNamara JR., Ordovas JM., Silberman SR., Wilson PW., and Schaefer EJ.** Prevalence of Lipoprotein (a) Excess in Coronary Disease. *Am J Cardiol.* 67: 1039-1045, (1991).
- * **Georg G., Gosta D., Kare B., Newton E. and Andrew L.** Lp (a) as a Risk Factor for Myocardial Infarction. *JAMA.* 256: 2540-2544. (1986).
- * **Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, and Lawn RM.** Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein (a). *Science* 260: 1655-8; (1993).
- * **Grundy S.** Cholesterol and CAD. *JAMA*; 264:3053. (1990).
- * **Grundy SM., and Vega GL.** Fibrin acids: Effects on Lipids and Lipoprotein Metabolism. *Am J Med*; 93:9-20 (1987).
- * **Grundy SM., Balady GJ., and Criqui MH.** Primary Prevention of Coronary Heart Disease: Guidance From Framingham. A Statement for Health Care Professionals From the AHA Task Force of Risk Reduction. *Circulation*; 97:1876-1887. (1998).
- * **Gurewich V.** The Sequential, Complementary, and Synergistic Activation of Fibrin-Bound Plasminogen by Tissue Plasminogen Activator and Pro-Urokinase. *Fibrinolysis*, 3:59-66 (1989).

- * **Havel RJ.** Post Prandial lipid metabolism, an overview. Proc. Nut. Soc. 56: 629 – 669 (1997).

- * **Hearn JA., Donohue BC., Ba'alkaki H., Douglas JS., King SPI. and Lembo NJ.** Usefulness of Serum Lipoprotein (a) as a Predictor of Restenosis after Percutaneous Transluminal Coronary Angioplasty. Am J Card; 69:736-739 (1992).

- * **Heidelbaugh J., and Raymond J.** Diagnosis and management of lipid disorders. Clinics in Family Practice,3(4); (2001).

- * **Hisham M., Kholief H., Sharaby M., Farid M., Abdel Salam M., Abdel Azeem A., and Saalama M.** Is lipoprotein (a) an independent risk factor for coronary artery disease? Sc. J. Az. Med. Fac. (Girls) 22(3) : 1463 – 1470. (2001).

- * **Hobbs H., White Al.:** lipoprotein (a) intrigues and insight. Curr. Opin. Lipidol 10 : 225 – 236 (1999).

- * **Hopkins PN., Wu LL. Hunt SC, James BC, Vincent GM, and Williams RR.** Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease, Arterioscler Thromb Vase Biol. J;7:2783-2792 (1997).

- * **Jacques G., Jennifer L., Judith R., Jose M., Steven R., Peter W., and Ernst J.:** Prevalence of Lipoprotein (a) [Lp(a)] Excess in Coronary Artery Disease. Am J Cardiol; 67:1039-1045. (1991).

- * **Jan G., Jens B., Peter S. and Christoph W.:** Impairment of Endothelium-Dependent Dilation in Rabbit Renal Arteries by Oxidized Lipoprotein (a). Role of Oxygen-Derived Radicals. Circulation; 92: 1582-1589. (1995).

- * **Jenner JL., Ordovas JM., Lamon-Fava S., Schaefer MM., Wilson PW., Castelli WP. and Schaefer I.** Effects of age, sex and menopausal status on Lp(a) levels: Framingham Off-spring Study. *Circulation*. 87:1135-1141. (1993)

- * **Jennifer L., Jose M., Stefania L., Mary M., Peter W., William P., and Ernst J.:** Effects of Age, Sex, and Menopausal Status on Plasma Lipoprotein (a) Levels The Framingham Offspring Study. *Circulation*; 87: 1135-1141. (1993).

- * **John A., and Antonio M.:** Dyslipidemia and Other Risk Factors for CAD. In *Heart Disease Textbook of Cardiovascular Medicine*. Braunwold E. (6th ed), W.B. Saunders Co., Philadelphia, 35:1126. (2001).

- * **Kamboh MI, Ferrell RE, and Kottke BA.** Expressed Hyper Variable Polymorphism of Apolipoprotein(a). *Am. J. Hum Genet.* 49: 1063-1074. (1991).

- * **Khan MA, and Baseer A.** Lipoprotein (a) Status in Coronary Heart Disease. *JAMA*; 50(2): 47-50 (Feb; 2000).

- * **Khoo J., Miller E., McLoughlin P., and Steinberg D.** Prevention of LDL Aggregation by HDL or Apolipoprotein A-1. *J Lipid Res* 31:645. (1990).

- * **Kronenberg F., Kronenberg M., Kiechl, S., Trenkwalder E., Oberhollenzer F., Egger G., Utermann G., and Willeit J.,** Role of Lipoprotein(a) and Apoprotein (a) Phenotype in Atherogenesis : Prospective Results From the Bruneck Study. *Circulation* 100: 1154-1160 (1999).

- * **Kruss R., Burke D., Butterfield G., and Lendgren F.** Identification of Multiple Subclasses of Plasma Low Density Lipoproteins in Normal Humans. *J Lip Res*; 23:14. (1982).
- * **Lackner C., Boerwinkle E., Leffert C., Rahmig T., and Hobbs H.** Molecular Basis of Apolipoprotein (a) Isoform Size Heterogeneity as Revealed by Puls-Field Gel Electrophoresis. *J. Clin. Invest.*; 87: 2153-2161; (1993).
- * **Ledue TB., Neveux LM., Palomaki GE., Ritchie RF. and Craig WY.** The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. *Clin Chim Acta.* 223:73-82. (1993).
- * **Maciejko, J., Holmes D., and Kottke B.:** Apolipoproteins AI as a Marker of Angiographically Assessed Coronary Artery Disease. *N. Engl. J. Med.*, 309: 385-389, (1983).
- * **Maeda S., Abe A., Seishima M., Makino K., Noma A., and Kawade M.** Transient Changes of Serum Lipoprotein(a) as an acute phase protein. *Atherosclerosis*; 78:145-150 (1989).
- * **Maher V, Brown BG, and Marcovina SM.** Lowering LDL cholesterol levels to offset effects of elevated lipoprotein(a) levels *Canadian Medical Association Journal*; 154: 1533-1534 (1996).
- * **Marburger C, Hambrecht R, Niebauer J et al.** Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men- *Am J Cardiol*, 73 : 742-46 (1994)
- * **Marek N., Elizabeth S., and Jean D.:** Oxidative Modification of Lipoprotein (a) and the Effect of B-Carotene. *Metabolism*; 41 (11): 1215- 1224. (November, 1992).

- * **McNamara JR., and Schaefer EJ.** Automated Enzymatic Standardized Lipid Analyses for Plasma and Lipoprotein Fractions. Clin Chim Acta; 166: 1-8 (1987)

- * **Miwa K, Nakagawa K, Yoshida N, Taguchi Y and Inoue H.** Lipoprotein(a) is a Risk Factor for Occurrence of Acute Myocardial Infarction in Patients With Coronary Vasospasm. J. Am. Coll. Cardiol.; 35 (5): 1200-5. (Apr; 2000). (PubMed medline).

- * **Moliterno DJ, Lange RA, Meidell RS and Hillis LD.** Relation of Plasma Lipoprotein (a) to Infarct Artery Patency in Survivors of Myocardial Infarction. Circulation; 88:935-940 (1993).

- * **Moreno P., Falk E., Palacios IF., Newell JB., Fuster V., Fallon JT.** Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 90: 2844 – 50. (1994).

- * **Naito H.** The Association of Serum Lipids, Lipoproteins and Apolipoproteins With Coronary Artery Disease Assessed by Coronary Arteriography. Ann. N.Y. Acad Sci., 454: 230-238, (1986).

- * **Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, and Abu-Lebdeh HS.** Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation,96:1390-1397. (1997)

- * **Ohasi H, Oda H., Ohno M., Watanabe S., and Sakata S.** Lipoprotein (a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int. Suppl.; 71: S242-4. (Jul; 1999).

- * **Orth K., Mittleman, M., Schenck K., Wamala S., Eriksson M.,**

- Belkic K., Kirkeeide R., Svane B., and Ryden L.* Lipoprotein(a) as a Determinant of Coronary Heart Disease in Young Women. *Circulation* 95: 329-334.(1997).
- * *Ovalle F, and Bell D.* Troglitazone's effect on lipoprotein(a) levels, *Diabetes care* 22:859-860, (1999.)
- * *Patton C., and Grouch S.* Spectrophotometric and Kinetic Investigation of the Berthelot Reaction for Determination of Ammonia. *Anal. Chem.*, 49:464 (1977).
- * *Paultre F., Pearson T., Weil H., Tuck C., Myerson M., Rubin t, Francis C. Marx H., Philbin, E., Reed R., and Berglund L.* High Levels ofLp(a) With a SmaU Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men. (*Arteriosclerosis, Thrombosis, and Vascular Biology*)20: 2619-2624.(2000)
- * *Poon M., Zhang X., Dunsky K., Taubman MB., and Harpel PC.* Apolipoprotein (a) induces monocyte chemotactic activity in human vascular endothelial cells. *Circulaion.* 96-2514-19.(1997)
- * *Ragab MS., Selvaraj P. and Sgouias DS.* Oxidized lipoprotein (a) induces cell adhesion molecule Mac1(CD 11b) and enhances adhesion of the monocytic cell line new 937 to cultured endothelial cells. *Atherosclerosis* 123:103-13.(1996).
- * *Raitakari O., Adams M. and Celermajer D.* Effect ofLp(a) on the Early Functional and Structural Changes of Atherosclerosis, (*Arteriosclerosis, Thrombosis, and Vascular Biology*)19: 990-995 (1999).
- * *Ratella G., Liedtke R. and Wermus G.* Automated Enzymatic Measurment of Total Cholesterol in Serum. *Clin chem.*, 24: 470 (1978).

- * **Rath M., Niendorf A. and Reblin T.** Detection and Quantitation of Lipoprotein (a) in the Arterial Wall of 107 Coronary Bypass Patients. *Arteriosclerosis* 9: 579-692, (1995).
- * **Raul A., Ian D., Jan P., Robert C. and Juan C.** Elevated plasma Lipoprotein (a) Is Associated With Coronary Artery Disease in Patients With Chronic Stable Angina Pectoris. *J. Am. Coll. Cardiol.*; 31: 1260-6. (1998).
- * **Real JT., Ascaso JF., Chaves FJ., Tenes S., Pries MA., Puig O., Armengod ME. and Carmena R.** Plasma Lp (a) Values in Familial Hypercholesterolemia and Relation to Coronary Heart Disease. *Nutr Metab Cardiovasc Dis*; 9(1): 41-4. (Feb; 1999) (PubMed medline).
- * **Rene L., Ian J., Carlos R., Sarah M., Eric R. and Lawrence W.** Elevated Serum Lipoprotein (a) Is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty *Circulation*; 91: 1403-1409. (1995).
- * **Ridker PM., Hennekens CH. and Stampfer MJ.** A prospective study of lipoprotein (a) and the risk of myocardial infarction. *JAMA*; 270:2195-2199. (1993).
- * **Rim L., Ali B., Slim BA. and Bechir Z.** Lipoprotein (a), A New Risk Factor for Coronary Artery disease. *Tunis Med.*; 78(11): 648-52 (Nov, 2000), (from PubMed on line).
- * **Ron K. and Santa R.** Lipoprotein(a), Vascular Disease, and Vitamin C. *The doctors' Medical Library Web Doctor*. (2001).
- * **Rosengren A., Wilhelmsen L., Eriksson E., Risberg B. and Wedel H.** Lipoprotein (a) and Coronary Heart Disease in a General Population Sample of Middle Aged Men. *BMJ*, 301: 1248-1250; (1990).

- * ***Ross R.*** The Pathogenesis of Atherosclerosis. In Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. Vol 2. 5th ed. Philadelphia: WB Saunders Co; 1105-1125. (1997).

- * ***Sandholzer E., Boerwinkle N., Saha M., and Utermann G.*** Apolipoprotein (a) Phenotypes, Lp (a) Concentration and Plasma Lipid levels in Relation to Coronary Heart Disease in a Chinese Population: Evidence for the Role of the apo (a) Gene in Coronary heart Disease J. Clin. Invest. 89: 1040-1046. March (1992).

- * ***Santica M., Hal K., Gabriele B., Giuseppe C., Claudio G., Edoardo C., Massimo P., and Paolo P.*** Fish Intake, Independent of Apo (a) Size, Accounts for Lower Plasma Lipoprotein (a) Levels in Bantu Fishermen of Tanzania: The Lugalawa Study Arterioscler. Thromb. Vasc. Biol; 19:1250-1256. (1999).

- * ***Schachinger V., Halle M., Minners J., Berg A. and Zeiher AM.*** Lipoprotein (a) selectively impairs receptor – mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 30 (4), 927 – 34 (1997)

- * ***Schaefer E., Blum C. and Levy R.*** Metabolism of High Density Lipoprotein, Apolipoproteins in Tangier Disease. N. Eng. J. Med., 299: 905-910, (1978).

- * ***Schaefer E., Stefania L., Jennifer L., Judith R., McNamara MT., Jose M., Edward D., Jeffrey M., Abolafia M., Kenneth L. and Robert I.*** Lipoprotein (a) Levels and Risk of Coronary Heart Disease in Men The Lipid Research Clinics Coronary Prevention Trial. JAMA; 271: 999-1003. (1994).

- * ***Schachinger V., Halle M., Minners J., Berg A. and Zeiher AM.*** Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. Am Coll

- Cardiol.1997,30:927-934. (1997)
- * ***Schawtzman RA., Cox ID., Poloniecki J., Crook R., Seymour CA., and Kaski S.*** Elevated Plasma Lipoprotein associated with coronary artery disease in patients with chronic stable pectoris. Am Coll Cardiol. 31(6)1260-66. (1998).
 - * ***Schlueter W., Keilani T. and Battle DC.*** Metabolic Effects of Converting Enzyme Inhibitors: Focus on the Reduction of Cholesterol and Lipoprotein(a) by Fosinopril. Am J Cardiol; 72:37H–44H (1993).
 - * ***Seed M., Hoppichler F. and Reaveley D.*** Relation of Serum LP (a) Concentration and Apolipoprotein (a) Phenotype According to Hypercholesterolaemia . N Engl J Med; 32: 1494-9. (1990).
 - * ***Shilpak MG., Simon JA., Vittinghoff E., Lin F., Barrett E, Knopp RH. and Levy RI.*** Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after manopause. JAMA; 12: 283 (14): 1845-52. (Apr; 2000). (From PubMed medline).
 - * ***Slunga L., Asplund K., Johnson O. and Dahlen GH.*** Lipoprotein (a) in a Randomly Selected 25–64 Year Old Population: The Northern Sweden Monica Study. J Clin Epidemiol; 46:617–624 (1993).
 - * ***Slyper AH.*** Low-Density Lipoprotein Density and Atherosclerosis: Unraveling the Connection. JAMA; 272(4): 305-8. (1994).
 - * ***Sniderman AD., Brown BG., Stewart FF. and Cianflone K.*** From familial combined hyperlipidemia to hyperapoB: unraveling overproduction of hepatic apoB lipoproteins. Curr Opin Lipidol. 3: 137 – 142. (1992).
 - * ***Takami S., Yamashita S., Kihara S., Ishigami M., Takemura K.,***

- Kume N., Kita T. and Matsuziwa Y.*** Lipoprotein(a) enhances the expression of intracellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. *Circ.*97:721-728. (1998)
- * ***Terres W., Tatsis E., Pfalzer B., Beil FU., Beisiegel U. and Hamm CW.*** Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). *Circulation* 91: 948 – 950. (1995).
- * ***Tesra R. and Marcovina SM.*** The Rate of Plasmin Fomation After in Vitro Clotting is Inversely Related to Lipoprotein (a) Plasma Levels. *Int J Clin Lab Res*; 29 (3): 128-32. (1999).
- * ***Tomlinson J., McLean J. and Lawn R.*** Rhesus Monkey Apolipoprotein(a): Sequence Evolution and Site of Synthesis. *J. Boil> Chem.* 264: 5957-5965. (1989).
- * ***Topol E.*** Manual of Cardiovascular Medicine Text Book. 1st Edition (1998).
- * ***Ullrich H., Lackner KJ., and Schmitz G.*** Lipoprotein (a) apheresis in severe coronry heart disease: an immunoadsorption method. *Artif Organs USA*; 22(2) 135-9. ISSN: 0160-564X. (1998 from PubMed medline).
- * ***Utermann F., Hoppichler H., Dieplinger M., Seed G. and Thompson B.*** Defects in the Low Density Lipoprotein Receptor Gene Affect Lipoproten (a) Levels: Multiplicative Interaction of Two Gene Loci Associated With Premature Atherosclerosis. *Proc. Natl. Acad USA Genetics*; 86: 4171-4174, June (1989).

- * *Utermann G.* The Mysteries of Lipoprotein (a). *Science*; 2456: 904-910 (1989).

- * *Watts GF., Mandalia S., Slavin B., Brunt J., Coltart DJ. and Lewis B.* Metabolic determinant of the course of coronary artery disease in men. *Clin Chem* 40: 2240-46 (1994).

- * *White AL. and Lanford RE.* Biosynthesis and metabolism of lipoprotein (a). *Curr Opin Lipidol*; 6:75-80. (1995).

- * *Wissler R.* Principles of the Pathogenesis of Atherosclerosis. In Braunwald E. *Heart Disease. A text book of Cardiovascular Medicine*, 2nd edition, Philadelphia W.B. Saunders, 1183. (1984).

- * *Wolfram T., Efstratios T., Benjamin P., Ulrich B., Ulrike B. and Christian W.* Rapid Angiographic Progression of Coronary Artery Disease in Patients With Elevated Lipoprotein (a). *Circulation*. 91: 948-950; (1995).

- * *Yamada S., Morishita R., Nakamura S., Ogihara, T., Kusumi Y., Sakurai I., Kubo N. and Sakurabayashi I.* Development of Antibody Against Epitope of Lipoprotein (a) Modified by Oxidation : Evaluation of New Enzyme-Linked Immunosorbent Assay for Oxidized Lipoprotein (a). *Circulation* 102: 1639 – 1644 (2000).

- * *Yamamoto H., Michinori I., Takashi Y., Hironori U., Yoshihiro H. and Michio Y.* Risk Factors for Restenosis After Percutaneous Transluminal Coronary Angioplasty: Role of Lipoprotein (a). *Am. Heart J.*; 130:1168-73. (1995).

- * *Yutaka I., Masayuki Y., Masahiro I., Hiroshi I., Kenji O. and Yoshifusa A.* Elevated Serum Lipoprotein (a) Is a Risk Factor for Left Atrial Thrombus in Patients with Chronic Atrial Fibrillation: A

Transesophageal Echocardiographie Study. Am Heart J. 136 (6) 965-971, (1998).

- * *Zhao S., Li X. and Wang Z.* Plasma levels of lipids, lipoproteins and apolipoproteins affected by endogenous testosterone. Human I Ko To Hsueh Pao; 23 (3): 299-301. (1998). (from Pub Med medline).
- * *Zujun Z., Katherine C. and Allan D.* Role of Cholesterol Ester Mass in Regulation Of secretion Of ApoB100 Lipoprotein Particles by Hamster Hepatocytes and Effects of Statins on That Relationship. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:743-752 (1999).